Eating on GLP-1 Medications

GLP-1 receptor agonists (semaglutide, tirzepatide, and related drugs) slow gastric emptying and act on appetite centers in the brain, producing much stronger and earlier fullness than most people are used to. The practical effect is a sharp drop in the total volume of food eaten — a narrative review of dietary intake studies in patients on GLP-1 and dual GIP/GLP-1 receptor agonists found total caloric intake fell by roughly 16–39% after starting treatment. That reduction in volume is the whole mechanism behind the weight loss, but it also means every bite has to work harder nutritionally: eating noticeably less food raises the real risk of falling short on protein, fiber, and micronutrients like iron, B12, vitamin D, and calcium, simply because there isn't as much food left in the day to carry them.

Read the narrative review (Obesity Pillars, 2024) →

A well-documented finding across the major GLP-1 trials is that a meaningful share of the weight lost on these drugs is lean mass, not fat. In the SURMOUNT-1 body-composition substudy of tirzepatide (DXA scans in 160 participants over 72 weeks), body weight fell 21.3%, fat mass fell 33.9%, and lean mass fell 10.9% with tirzepatide — meaning roughly 25% of the total weight lost was lean mass, versus about 75% fat, a split the authors described as similar in proportion to other weight-loss methods, including diet alone.

Read the SURMOUNT-1 body composition substudy →

A comparable DXA substudy from the STEP 1 semaglutide trial (140 participants) reported the same general pattern — fat mass dropped by more than lean mass in relative terms, but lean mass still made up a meaningful share of total weight lost.

Read the STEP 1 body composition analysis →

Higher protein intake, paired with resistance training, is the main lever for limiting this.The 2025 joint advisory on nutrition for GLP-1 therapy notes that targets of 1.2 to 1.6 g of protein per kg of body weight per day have been proposed during active weight reduction. Alternatives it describes are about 1.5 g per kg of fat-free mass, or a flat 80 to 120 g a day. All of these are well above the 0.8 g/kg RDA. The advisory also says prolonged intake at or above 2 g/kg/day should be avoided, and that more protein alone is likely not enough to preserve muscle without structured resistance training.

Read the joint advisory →

A 2025 case series of three patients who prioritized lean-tissue preservation described typical intakes of 1.6 to 2.3 g per kg of fat-free mass (0.7 to 1.7 g per kg of total body weight), alongside resistance training 3 to 5 days a week. That describes what three people ate, not a recommended target. Our Protein Calculator uses a 1.6 to 2.2 g/kg/day range for its cutting/active tier, drawn from resistance-training research in people not taking these drugs, so its upper end sits above the advisory's caution on long-term intake. Since GLP-1 medications sharply reduce how much food fits in a day, reaching any of these targets usually means eating protein-dense foods first at each meal, such as eggs, dairy, poultry, fish, tofu, legumes, or a protein supplement, rather than spreading limited appetite across lower-density foods.

Read the lean-tissue preservation case series →

Nausea, constipation, and other GI symptoms are common on GLP-1 drugs. In the Wegovy (semaglutide) weight reduction trials, 73% of adults on the drug reported GI side effects, compared with 47% on placebo. These symptoms are a direct consequence of the same delayed gastric emptying that drives appetite suppression. A 2024 clinical review of dietary management for these symptoms recommends smaller, more frequent meals instead of a few large ones, since a large meal sits in an already-slower stomach longer and is more likely to trigger nausea. It also recommends avoiding high-fat, greasy, or fried foods, which slow gastric emptying further and are a common nausea trigger, and eating more slowly while stopping at the first sign of fullness rather than pushing through it.

Read the Wegovy prescribing information →

Read the dietary management review (DMSO, 2024) →

For constipation specifically — one of the most common complaints — adequate fiber and fluid intake matter more than usual, since the same slowed transit that helps with appetite also slows things down further along the gut. Our Fiber page covers the actual intake targets and why a gradual ramp-up (not a sudden jump) matters, and our Water Intake Calculator can help make sure fluid intake hasn't quietly dropped along with food volume — easy to happen when appetite for both is suppressed at once.

This page covers food choices only. It does not provide dosing, titration schedules, injection technique, or any other administration guidance for semaglutide, tirzepatide, or any other GLP-1 medication — that information belongs with your prescriber, who sets and adjusts your specific regimen. It's also not a substitute for personalized medical or nutrition advice: if you're experiencing significant nausea, vomiting, rapid weight loss, or signs of nutrient deficiency while on one of these medications, talk to the provider who prescribed it, and consider asking for a referral to a registered dietitian — several of the clinical reviews cited on this page specifically call out a lack of structured nutrition guidance for patients starting GLP-1 therapy.